Dr. Cohen Discusses Combination Therapy in MCL

Video

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses combination therapy for patients with mantle cell lymphoma.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses combination therapy for patients with mantle cell lymphoma (MCL).

There is a lot of interest in incorporating novel treatments into the management of patients with MCL, Cohen says. This includes the possibility of eliminating chemotherapy in the frontline setting. There are mature data suggesting that rituximab (Rituxan) plus lenalidomide (Revlimid) will induce a prolonged remission in patients with MCL. Although patients may have to stay on this combination for a long period of time, Cohen says that the toxicities seem tolerable.

Cohen says that combinations with novel agents are likely going to be the future of MCL treatment. While cytarabine is felt to be an important part of the chemotherapy backbone, it does not work for all patients. For example, patients with TP53 mutations do not respond well to cytarabine-based intensive therapy. For those patients, Cohen says that novel combinations are under investigation.

Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
© 2024 MJH Life Sciences

All rights reserved.